Form 4: IN8BIO Director Peter Brandt Buys 72,464 Shares

IN8BIO Director Peter C. Brandt acquired 72,464 shares of common stock at $1.38 per share, increasing his beneficial ownership.

Summary

• Director Peter C. Brandt acquired 72,464 shares of IN8BIO, INC. common stock.
• The transaction occurred on December 22, 2025, at a price of $1.38 per share.
• Following the transaction, Brandt directly owns 95,181 shares and indirectly owns 3,509 shares through The Peter C. Brandt 2020-4 GRAT.
• The reported share numbers reflect a 1-for-30 reverse stock split that became effective on June 3, 2025.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director generally indicates a positive outlook on the company's future performance and valuation, suggesting insider confidence.

Positives

• A director's acquisition of shares indicates confidence in the company's future prospects.
• The purchase price of $1.38 per share suggests a valuation point at which the insider sees value.

Future Outlook

NA

Industry Context

Insider buying in biotechnology companies can signal confidence in upcoming clinical trial results or regulatory approvals, which are critical value drivers in the sector.

Related Party Transactions

• Peter C. Brandt indirectly holds 3,509 shares through The Peter C. Brandt 2020-4 GRAT, for which he serves as trustee, indicating a related party transaction structure for a portion of his beneficial ownership.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal of confidence in the company's future, potentially influencing investor sentiment.
• The transaction itself does not directly impact employees, customers, suppliers, or creditors beyond general market perception.

Key Dates

Recommendation

The director's purchase of a significant block of shares at a specific price point suggests strong insider confidence in IN8BIO's valuation and future prospects. This action, while positive, typically warrants a 'hold' recommendation for seasoned investors to allow for further analysis of the company's fundamentals and market reaction, rather than an immediate 'buy' based solely on an insider transaction.

Keywords

IN8BIO, INAB, Peter C. Brandt, Director, Stock Purchase, Insider Trading, Form 4, Common Stock, Reverse Stock Split, Biotechnology